UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Frontiers in immunology, 2021-10, Vol.12, p.724443-724443

2021

Volltextzugriff (PDF)

Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation

Frontiers in medicine, 2022-01, Vol.8, p.772998

2022

Volltextzugriff (PDF)

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma

Neoplasia (New York, N.Y.), 2021-09, Vol.23 (9), p.870-878

2021

Volltextzugriff (PDF)

Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity

Cellular physiology and biochemistry, 2018, Vol.49 (1), p.235-244

2018

Volltextzugriff (PDF)

Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities

Cancer cell international, 2024-02, Vol.24 (1), p.84-84, Article 84

2024

Volltextzugriff (PDF)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC

Open life sciences, 2023-03, Vol.18 (1), p.20220533-20220533

2023

Volltextzugriff (PDF)

Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways

Oncology reports, 2012-03, Vol.27 (3), p.783-790

2012

Volltextzugriff (PDF)

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

Discover. Oncology, 2023-06, Vol.14 (1), p.89-89, Article 89

2023

Volltextzugriff (PDF)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Scientific reports, 2017-08, Vol.7 (1), p.8483-8, Article 8483

2017

Volltextzugriff (PDF)

Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro

Oncology reports, 2011-11, Vol.26 (5), p.1157-1164

2011

Volltextzugriff (PDF)

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Journal of the National Cancer Center, 2023-12, Vol.3 (4), p.256-265

2023

Volltextzugriff (PDF)

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.e85-e88

2019

Volltextzugriff (PDF)

The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer

Zhongguo fei ai za zhi, 2011-07, Vol.14 (7), p.598-605

2011

Volltextzugriff (PDF)

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Journal of clinical oncology, 2023-01, Vol.41 (3), p.651-663

2023

Volltextzugriff (PDF)

An Algorithm for Path Planning of Autonomous Ships Considering the Influence of Wind and Wave

Journal of physics. Conference series, 2021-11, Vol.2083 (3), p.32028

2021

Volltextzugriff (PDF)

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC

Scientific reports, 2016-02, Vol.6 (1), p.21359-21359, Article 21359

2016

Volltextzugriff (PDF)

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Journal of thoracic oncology, 2021-08, Vol.16 (8), p.1403-1414

2021

Volltextzugriff (PDF)

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1959-1963

2021

Volltextzugriff (PDF)

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.628-639

2023

Volltextzugriff (PDF)

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Cancer cell, 2024-09, Vol.42 (9), p.1598-1613.e4

2024

Volltextzugriff (PDF)

Monitoring antiangiogenesis of bevacizumab in zebrafsh

Drug design, development and therapy, 2018-01, Vol.10, p.2423

2018

Volltextzugriff (PDF)

Monitoring antiangiogenesis of bevacizumab in zebrafish

Drug design, development and therapy, 2018-01, Vol.12, p.2423-2430

2018

Volltextzugriff (PDF)

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature

Annals of translational medicine, 2021-08, Vol.9 (16), p.1358-1358

2021

Volltextzugriff (PDF)

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Translational lung cancer research, 2022-06, Vol.11 (6), p.1038-1050

2022

Volltextzugriff (PDF)

Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study

Annals of translational medicine, 2022-09, Vol.10 (18), p.967-967

2022

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Englisch
(79)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(35)
Humans
(23)
Oncology
(17)
Chemotherapy
(9)
Female
(8)
Ligands
(8)
Lung Cancer
(8)
Male
(8)
Middle Aged
(8)
Aged
(7)
Lung Neoplasms - Drug Therapy
(7)
Binding Sites
(6)
Lung Neoplasms - Pathology
(6)
Mutation
(6)
Technology
(6)
Tumors
(6)
Adult
(5)
Cancer Therapies
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma

Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity

Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC

Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy

The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

An Algorithm for Path Planning of Autonomous Ships Considering the Influence of Wind and Wave

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Monitoring antiangiogenesis of bevacizumab in zebrafsh

Monitoring antiangiogenesis of bevacizumab in zebrafish

Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study

Suchergebnisse filtern